Insights

Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has […]

Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Read More »

Dementias Platform UK: TRANSLATIONS 2025

Dementias Platform UK: TRANSLATION 2025 Martina De Lillo, Clinical Scientist We recently attended TRANSLATION 2025, organized by Dementia Platform UK, where experts shared groundbreaking developments in treatment approaches, diagnostic methods, and research methodologies. The presentations revealed a field undergoing rapid transformation, with significant implications for patients and healthcare professionals alike. The theme of the conference

Dementias Platform UK: TRANSLATIONS 2025 Read More »

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial Read More »

Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions 

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase

Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  Read More »

Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions 

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase

Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  Read More »

Actigraphy and wearable sensor technologies to enhance assessment in health conditions

Actigraphy and wearable sensor technologies to enhance assessment in health conditions affecting motor function and behaviour Reflections from the 2025 Actigraph Digital Data Summit​ The 2025 ActiGraph Digital Data Summit in Pensacola, FL, provided a valuable environment for exploring the benefits and challenges of using actigraphy, and other wearable sensor technologies, to enhance assessment in

Actigraphy and wearable sensor technologies to enhance assessment in health conditions Read More »

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted  Read More »

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment Read More »

Scroll to Top